YTTRIUM Y-90 EPRATUZUMAB TETRAXETAN

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Description
Sources: https://www.ema.europa.eu/en/documents/product-information/yttriga-epar-product-information_en.pdf | https://www.ema.europa.eu/en/documents/product-information/ytracis-epar-product-information_en.pdf

YTTRIUM Y-90 (YTRACIS®, YTTRIGA®) is a radioactive form of the chemical element yttrium. It is used for radiolabelling other medicines. An example of its use is the treatment of some type of tumors, where the radiolabelled medicine carries the radioactivity to the site of a tumor to destroy the tumor cells.

Approval Year

Substance Class	Protein Created by `admin` on `Mon Mar 31 20:43:17 GMT 2025` Edited by `admin` on `Mon Mar 31 20:43:17 GMT 2025`
Protein Type	MONOCLONAL ANTIBODY CONJUGATE
Protein Sub Type	IGG1
Sequence Origin	HUMANIZED MOUSE
Sequence Type	COMPLETE
Record UNII	J36232195E
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

YTTRIUM Y 90 EPRATUZUMAB TETRAXETAN

Preferred Name

English

YTTRIUM Y-90 EPRATUZUMAB TETRAXETAN

Common Name

English

90Y-EPRATUZUMAB

Common Name

English

(SUP 90)Y-DOTA-HLL2

Common Name

English

S9S0Y-DOTA-HLL2

Code

English

2F35K89X9W

Code

English

90Y-DOTA-HLL2

Code

English

YTTRIUM Y 90 EPRATUZUMAB TETRAXETAN [MI]

Common Name

English

YTTRIUM Y 90 EPRATUZUMAB TETRAXETAN [USAN]

Common Name

English

EPRATUZUMAB TETRAXETAN YTTRIUM Y-90

Common Name

English

Y-90-DOTA-HLL2

Common Name

English

YTTRIUM (90Y) EPRATUZUMAB TETRAXETAN

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1511

Created by admin on Mon Mar 31 20:43:17 GMT 2025 , Edited by admin on Mon Mar 31 20:43:17 GMT 2025

NCI_THESAURUS

C129819

Created by admin on Mon Mar 31 20:43:17 GMT 2025 , Edited by admin on Mon Mar 31 20:43:17 GMT 2025

Code System Code Type Description

EVMPD

SUB129631

Created by admin on Mon Mar 31 20:43:17 GMT 2025 , Edited by admin on Mon Mar 31 20:43:17 GMT 2025

PRIMARY

MERCK INDEX

m4957

Created by admin on Mon Mar 31 20:43:17 GMT 2025 , Edited by admin on Mon Mar 31 20:43:17 GMT 2025

PRIMARY

Merck Index

NCI_THESAURUS

C2582

Created by admin on Mon Mar 31 20:43:17 GMT 2025 , Edited by admin on Mon Mar 31 20:43:17 GMT 2025

PRIMARY

ChEMBL

CHEMBL2108666

Created by admin on Mon Mar 31 20:43:17 GMT 2025 , Edited by admin on Mon Mar 31 20:43:17 GMT 2025

PRIMARY

CAS

501423-25-2

Created by admin on Mon Mar 31 20:43:17 GMT 2025 , Edited by admin on Mon Mar 31 20:43:17 GMT 2025

PRIMARY

SMS_ID

300000055502

Created by admin on Mon Mar 31 20:43:17 GMT 2025 , Edited by admin on Mon Mar 31 20:43:17 GMT 2025

PRIMARY

FDA UNII

J36232195E

Created by admin on Mon Mar 31 20:43:17 GMT 2025 , Edited by admin on Mon Mar 31 20:43:17 GMT 2025

PRIMARY

SMS_ID

300000044465

Created by admin on Mon Mar 31 20:43:17 GMT 2025 , Edited by admin on Mon Mar 31 20:43:17 GMT 2025

PRIMARY

From	To
1_22	1_96
1_143	1_199
1_219	3_219
1_225	2_225
1_228	2_228
1_260	1_320
1_366	1_424
2_22	2_96
2_143	2_199
2_219	4_219
2_260	2_320
2_366	2_424
3_23	3_94
3_139	3_199
4_23	4_94
4_139	4_199

Related Record Type Details


					7X6143A60Y

EPRATUZUMAB-CYS-TESIRINE

PARENT -> DERIVATIVE

Comments:

test

Amount:


					3062P60MH9

DERIVATIVE -> PARENT

Comments:

test

Amount:


					RCH7C9TW12

B-CELL RECEPTOR CD22

TARGET -> INHIBITOR


					J36232195E

YTTRIUM Y-90 EPRATUZUMAB TETRAXETAN

PARENT -> DERIVATIVE

Amount:

Related Record Type Details


					433ME2ATHW

YTTRIUM Y-90 CATION

ACTIVE MOIETY


					J36232195E

YTTRIUM Y-90 EPRATUZUMAB TETRAXETAN

ACTIVE MOIETY

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
FRAGMENT			LYSINE		LYSINE-DOTA	KTZ0L57AI1
MOIETY			LYSINE		YTTRIUM Y-90 CATION	433ME2ATHW

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Molecular Formula	CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL